Scancell (LON:SCLP) Trading 29.8% Higher – Time to Buy?

Scancell Holdings plc (LON:SCLP) shares shot up 29.8% on Monday . The company traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.15). 10,537,342 shares were traded during mid-day trading, an increase of 1,073% from the average session volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Price Performance

The company has a 50-day simple moving average of GBX 8.51 and a 200-day simple moving average of GBX 10.85. The company has a market cap of £103.47 million, a price-to-earnings ratio of -15.32 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.

Scancell (LON:SCLP) last announced its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. As a group, research analysts predict that Scancell Holdings plc will post -2.5361112 earnings per share for the current year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.